Coya Therapeutics in BTIG KOL Call on Alzheimer’s & GLP-1
Coya Therapeutics is advancing COYA 303, a combination therapy of low-dose interleukin-2 (COYA 301) and a GLP-1 receptor agonist,...
Castle Creek Biosciences Secures $75M Royalty Financing
Ligand Pharmaceuticals has invested $50 million and led a syndicate of co-investors, including Paragon Biosciences, Valor Equity Partners, and...
Oric Pharmaceuticals Announces Development Plans, Cash Runway, and Milestones
ORIC Pharmaceuticals announced focused development plans for its lead programs, ORIC-944 and ORIC-114, extending its cash runway into 2027....
FDA Accepts Medincell and Teva Uzedy for Bipolar I Disorder Treatment
Teva Pharmaceuticals and Medincell announced that the FDA accepted their supplemental New Drug Application for UZEDY, a long-acting injectable...
Elixirgen Therapeutics First Gene Therapy Trial Shows Telomere Elongation
Elixirgen Therapeutics announced positive Phase 1/2 clinical trial data for EXG-34217, a novel therapy for Telomere Biology Disorders (TBDs)....
Trethera & UCLA Publish Data on TRE-515 in Mice with MS
Trethera Corporation announced research published in Immunology demonstrating that their drug, TRE-515, effectively inhibits the hyperactive lymphocytes responsible for...
FemBloc Permanent Birth Control: Positive Safety and Efficacy Results
Femasys Inc. announced positive clinical trial data for FemBloc, a non-surgical permanent birth control method, published in the Journal...
Silexion Announces Promising Pancreatic Cancer Study Results
Silexion Therapeutics (NASDAQ: SLXN) has completed data collection for its first study of SIL-204 in orthotopic pancreatic cancer models....
Ampligen and Imfinzi in Phase 2 Pancreatic Cancer Trial
AIM ImmunoTech has dosed the first patient in Phase 2 of its Phase 1b/2 clinical trial, DURIPANC, evaluating Ampligen...
Alzamend Neuro Starts Phase 2 Trial of AL001 at Mass General
Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system,...